Brief: Cabaletta Bio Outlines Strategic Priorities And Anticipated Key Milestones For 2025
13/01/2025 14:27
Jan 13 (Reuters) - Cabaletta Bio Inc CABA.O :
* CABALETTA BIO OUTLINES STRATEGIC PRIORITIES AND
ANTICIPATED KEY
MILESTONES FOR 2025
* CABALETTA BIO INC - CABALLETTA TO MEET FDA ON RESE-CEL
TRIAL
DESIGNS IN 1H25
Source text: ID:nGNXBmqMx
Further company coverage: CABA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cabaletta Bio
See all newsCabaletta Bio Q1 net loss widens as R&D costs rise
Brief: First Patients Dosed With Cabaletta Bio’S Rese-Cel Manufactured On Cellares' Automated Cell Shuttle™ Platform
Brief: IND Amendment Clearance Obtained For Clinical Manufacturing Of Rese-Cel From Cabaletta Bio Using Cellares' Automated Platforms
Cabaletta Bio reports smaller-than-expected Q3 loss
U.S. RESEARCH ROUNDUP-Beacon Financial, Comerica, Doximity